An oncolytic virus is a virus that preferentially infects and kills cancer cells. As the infected cancer cells are destroyed by oncolysis, they release new infectious virus particles or virions to help destroy the remaining tumour. Oncolytic viruses are thought not only to cause direct destruction of the tumour cells, but also to stimulate host anti-tumour immune system responses.
The potential of viruses as anti-cancer agents was first realized in the early twentieth century, although coordinated research efforts did not begin until the 1960s. A number of viruses including adenovirus, reovirus, measles, herpes simplex, Newcastle disease virus, and vaccinia have been clinically tested as oncolytic agents. Most current oncolytic viruses are engineered for tumour selectivity, although there are naturally occurring examples such as reovirus and the Seneca virus, resulting in clinical trials.
Review Article: Journal of Neurology & Neurophysiology
Commentary: Journal of Neurology & Neurophysiology
Case Report: Journal of Neurology & Neurophysiology
Mini Review: Journal of Neurology & Neurophysiology
Review Article: Journal of Neurology & Neurophysiology
Posters & Accepted Abstracts: Journal of Neurology & Neurophysiology
Scientific Tracks Abstracts: Journal of Neurology & Neurophysiology
Scientific Tracks Abstracts: Journal of Neurology & Neurophysiology